Emergence of Ceftazidime–Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11 Klebsiella pneumoniae During Antibiotics Treatment
Mengxin Xu,Changrui Qian,Huaiyu Jia,Luozhu Feng,Shiyi Shi,Ying Zhang,Lingbo Wang,Jianming Cao,Tieli Zhou,Cui Zhou
DOI: https://doi.org/10.2147/IDR.S387187
2022-11-29
Infection and Drug Resistance
Abstract:Mengxin Xu, 1 Changrui Qian, 2 Huaiyu Jia, 1 Luozhu Feng, 3 Shiyi Shi, 1 Ying Zhang, 3 Lingbo Wang, 1 Jianming Cao, 3 Tieli Zhou, 1 Cui Zhou 1 1 Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, People's Republic of China; 2 School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China; 3 Department of Medical Laboratory Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, People's Republic of China Correspondence: Tieli Zhou; Cui Zhou, Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, 325035, People's Republic of China, Tel +86 0577 8668 9885, Email ; Introduction: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a serious threat to human public health. Ceftazidime–avibactam (CZA) is currently one of the few effective antibiotics for carbapenem-resistant Enterobacteriaceae (CRE). Methods and Results: Here, we analyzed two longitudinal Klebsiella pneumoniae clinical isolates (FK8578, FK8695) that were isolated from an ICU patient during antimicrobial treatment. Broth microdilution method, whole-genome sequencing (WGS) and comparative genomic analysis were used to elucidate the dynamics and mechanisms of antibiotic resistance. String test, quantification of capsule, biofilm inhibition test and Galleria mellonella ( G. mellonella ) infection model were used to explore the changes in virulence of the two clinical isolates. During antibiotic treatment, CRKP FK8578 underwent a series of drug resistance and virulence changes, including CZA resistance, carbapenem susceptibility and virulence attenuation. The results of WGS showed that mutation of bla KPC-2 to bla KPC-33 was responsible for the change of drug resistance phenotype between FK8578 and FK8695. pLVPK-like virulence plasmid without siderophore synthesis operon was identified in the two strains. On the other hand, the loss of hypermucoviscosity phenotype in the FK8695 strain may be related to a single nucleotide deletion of the rmpA gene, which would further lead to a decrease in virulence. Virulence results showed that compared with FK8578, FK8695 was negative in the string test, with decreased capsular production, smaller amounts of biofilm formation and higher survival rate of G. mellonella . Conclusion: This is the first report of CZA resistance and decreased virulence in ST11 CRKP strains during antimicrobial treatment. It is urgent to monitor CZA resistance and timely adjust anti-infective treatment strategies. Keywords: ceftazidime–avibactam, carbapenem-resistant Klebsiella pneumoniae , whole-genome sequencing, hypermucoviscosity, pLVPK-like plasmid, virulence attenuation Owing to the extensive use of carbapenems in clinical practice, the prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) increased globally, which poses a serious challenge to clinical treatment. 1 CZA is a novel β-lactam and β-lactamase inhibitor combination with the ability to inhibit the activity of AmpC, extended-spectrum β-lactamases (ESBLs), class A carbapenemases such as KPC and class D carbapenemases such as OXA-48 but not class B carbapenemases such as NDM, IMP and VIM 2,3 and has been considered as a last-resort treatment for severe infections caused by carbapenem-resistant Enterobacterales (CRE). Since the use of CZA was approved by the United States in 2015, the European Union in 2016, and China in 2019, the occurrence of CZA resistance has been increasingly reported worldwide. 4,5 In addition to CRKP, hypervirulent K. pneumoniae (hvKp) is another threat that causes severe community-acquired infections. The hypervirulence of K. pneumoniae was contributed to a virulence plasmid pLVPK which harbors capsular polysaccharides regulator genes rmpA / rmpA2 and some siderophore determinants. 6 Hypermucoviscosity (Hmv) phenotype is usually associated with hvKp, which was caused by the production of capsular polysaccharide (CPS) and the presence of virulence genes such as rmpACD / rmpA2 and magA . 7–9 Recently, the convergence of virulence and carbapenem resistance in K. pneumoniae has been reported, especially in China. 10 Carbapenem-resistant hvKp -Abstract Truncated-
pharmacology & pharmacy,infectious diseases